Gapping up
In reaction to earnings/guidance:
- TPB +3.8%, OTIS +2.9%, TMO +1.4%
M&A news:
- VIE +53.3% (to be acquired by Horizon Therapeutics (HZNP) for $53.00 per share in cash)
- THCB +44.2% (Microvast to list on Nasdaq through merger with Tuscan Holdings; Expected to be listed on the Nasdaq under the ticker symbol MVST following an anticipated transaction close in the second quarter of 2021)
- IFF +17.2% (to complete the previously announced merger of IFF and DuPont's (DD) Nutrition & Biosciences business, pursuant to a Reverse Morris Trust transaction today)
- HOLI +7.8% (confirmed it received a revised unsolicited consortium proposal to acquire all the outstanding shares of Hollysys for $17.10 per share)
- ASPL +6.3% (Wheels Up plans to become publicly-traded via SPAC merger with Aspirational Consumer Lifestyle Corp - to be listed on the New York Stock Exchange)
- KMDA +5.9% (entered into an agreement for the acquisition of the plasma collection center and certain related rights and assets from the privately-held Blood and Plasma Research)
Select Index ETFs showing early strength:
- QQQ +1.2%, IWM +1.2%, SPY +1.1%, DIA +0.8%
Other news:
- EXK +28.1% (grants Ridgestone Mining option to purchase Guadalupe y Calvo Project)
- GRTS +21.8% (files for mixed securities shelf offering, no amount given) API +21.3% (agrees to $250 mln private placement)
- AMC +18.1% (continued volatility in pre-mkt)
- DVAX +17.3% (Dynavax and CEPI announce $99 million in funding for CPG 1018 adjuvant manufacturing to support the global COVID-19 response; also, Dynavax and Clover announce planned global Phase 2/3 efficacy trial of adjuvanted COVID-19 vaccine candidate)
- ARQT +17.3% (reports topline results from pivotal DERMIS-1 and -2 Phase 3 trials of topical roflumilast cream)
- EH +17.2% (receives $40 mln investment from Carmignac)
- MBRX +14.7% (signed an agreement with Catalyst Clinical Research to manage its US clinical trial to study the ability of Annamycin to treat soft tissue sarcoma (STS) that has metastasized to the lungs)
- SRNE +14.2% (reports fourth patient also released from hospital following third infusion of stem cells)
- NVAX +10.4% (report that the co expects to produce up to 150 mln vaccine doses monthly by May or June, according to Reuters)
- SPCE +9.5% (provides flight test program update; new flight window set for VSS Unity rocket-powered flight from New Mexico)
- SMTS +8% (appoints Jose Vizquerra Benavides as Chairman)
- MICT +7.1% (has secured a significant follow-on purchase order of 5,000 SmartCam units, valued at approximately $1.5 million)
- ENG +6.4% (files for $100 mln mixed securities shelf offering)
- SAII +6.3% (Otonomo to list on Nasdaq through a business combination with Software Acquisition Group Inc. II )
- KSMT +5.7% (Nexters Global, the owner of Blockbuster Mobile Game Hero Wars, to go public via merger with Kismet Acquisition One)
- XPEV +5.3% (Jan deliveries)
- TLRY +4.5% (received the necessary approvals and market authorization in accordance with the Portuguese legislation to offer Tilray medical cannabis products in Portugal from its GMP-certified EU facility in Cantanhede, Portugal)
- KOSS +3.9% (continued volatility in pre-mkt)
- DPW +3.9% (to resume bitcoin mining at energy efficient facility with 1,000 S19 pro antminers from Bitmain)
- ARLP +3.6% (reported financial and operating performance for the quarter ended December 31, 2020)
- NIO +3% (Jan deliveries)
- BB +2.8% (continued volatility in pre-mkt)
- GDOT +2.5% (Starboard Value raises stake to 9.9% from 8.3%)
- GNOG +2% (Tilman Fertitta enters into deal to take Golden Nugget/Landry's Public)
Analyst comments:
- SB +11.5% (upgraded to Buy from Hold at Stifel)
- RCII +6.2% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)
- PAGS +5.2% (upgraded to Overweight from Neutral at JP Morgan)
- RGS +5.1% (upgraded to Buy from Hold at Loop Capital)
- OLN +4.4% (upgraded to Overweight from Neutral at JP Morgan)
- HAL +4.3% (upgraded to Overweight from Neutral at Piper Sandler)
- NKLA +3.5% (upgraded to Neutral from Underperform at Wedbush)
- TSLA +3.1% (target raised to a Street-high $1200 from $515 at Piper Sandler)
- NEXA +2.9% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- SNDR +2.8% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)
- UBSI +2.3% (upgraded to Outperform from Mkt Perform at Raymond James)